REGENXBIO's gene therapy for Hunter syndrome, showed 82% efficacy and strong safety in trials. Read more here.

Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026.

Datacolor has just announced the launch of the SpyderExpress, its most affordable display calibration tool yet – and it looks ...

Unsurprisingly, the X2D II's Raws provide superb amounts of detail at low ISOs, besting the single-shot performance of the ...